Previous Nav
Net Change on 11-09-2025
PersonalFN Rating
Category
Assets (Cr.)
Expense Ratio
Fund House
Launch Date
Benchmark
Minimum Investment (₹)
Minimum Addl Investment (₹)
Exit Load (%)
Minimum SIP Investment (₹)
Minimum STP Investment (₹)
Minimum SWP Investment (₹)
52 Week Low Nav (₹)
52 Week Low Nav Date
52 Week High Nav (₹)
52 Week High Nav Date
Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised
Sun Pharmaceutical Industries Limited
Divi's Laboratories Limited
Cipla Limited
Lupin Limited
Apollo Hospitals Enterprise Limited
Dr. Reddy's Laboratories Limited
MedPlus Health Services Limited
Vijaya Diagnostic Centre Limited
GlaxoSmithKline Pharmaceuticals Limited
Gland Pharma Limited
Ajanta Pharma Limited
Thyrocare Technologies Limited
Abbott India Limited
Sai Life Sciences Limited
Dr. Lal Path Labs Limited
Zydus Lifesciences Limited
Mankind Pharma Limited
Narayana Hrudayalaya Limited
Aurobindo Pharma Limited
JB Chemicals & Pharmaceuticals Limited
Alkem Laboratories Limited
Pfizer Limited
Biocon Limited
Sanofi India Limited
Suraksha Diagnostic Limited
Sanofi Consumer Healthcare India Limited
IPCA Laboratories Limited
Torrent Pharmaceuticals Limited
Fortis Healthcare Limited
Anthem Biosciences Limited
Syngene International Limited
Akums Drugs and Pharmaceuticals Limited
Emcure Pharmaceuticals Limited
AstraZeneca Pharma India Limited
Indoco Remedies Limited
Orchid Pharma Limited
Triparty Repo
Concord Biotech Limited
Net Current Assets
Cash Margin - CCIL
Pharmaceuticals & Drugs
Hospital & Healthcare Services
Retailing
Business Support
Miscellaneous
Cash
Equity
Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹8,357.03 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.
The NAV of Nippon India Pharma Fund ended up ₹1.79(0.35%)yesterday to ₹517.0466.
Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and
The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .
4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013